London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
SP now 34.3 - people realising what a solid forward looking company this is?
SP still rising, this could do very well.
buyers at 31 at close yesterday interest in ixico building
good buying at 31 late yesterday bodes well for today
They have been a little under the radar, good to see the SP strengthening.
The most exciting company in AIM which is hugely undervalued.
Over 30% of market cap placed .New buyers very beneficial and good for co . Brokers note after figures says BUY IXICO sees fair value at 62p which suggests substantial upside from current levels
5 holdings RNSs today - about 37% of the IXI shares in issue have changed hands as a result of this movement.
Vox markets post H1 report a week ago - IXI from 23 to 33 mins - 22% revenue growth - margins improving - breakeven for first time
https://bit.ly/2X5l2zB
have you read the RNSs? Look who bought them ;)
Looks like people dumping shares in huge volumes looking at the trades
Large trades reported :Hopefully this has cleared stock overhang . Directors and new broker Cenkos done Avery professional job
The first half of 2019 has been another period of significant progress. We have delivered on our first half financial targets, whilst developing our investment plans to ensure a strong full-year 2019 and beyond. You can clearly see the impact of our strategy in our revenue growth of 22% and continued strong gross margin performance. This points to the strength of the underlying business fundamentals and our growing position in an attractive market environment, delivering high value data analytics to our pharmaceutical and biotechnology clients. In the second half of 2019 we expect to accelerate the pace of our investment to enable further scale up in support of our long-term growth plans.
£7m cash and gone into profit. Looks interesting.
Very satisfactory figures and very positive outlook .this is becoming a a successful and well managed company with a very bright and profitable future. In my opinion these shares are very cheap..
is 30000 @28 booked 16,30 an early protected buy at limit of 28 or a sell at limit of 28, i suspect it might be a buy
Just taken a position
Moving higher.
Highlights:
· Reported revenues expected to be £3.43m for 6 months to 31 March 2019 (2018: £2.82m) representing growth of 22%.
· Strong closing cash balance of £7.5m as at 31 March 2019, includes the £5.5m oversubscribed placement in May 2018 (2018: £2.7m).
· Order book* stood at £21.2m as at 31 March 2019.
On the basis of the revenues for the first half, the Company remains confident that revenues for the full year to 30 September 2019 will be in line with market expectations of £6.6m. This would represent an increase of 22% over the prior year's reported revenue of £5.4m.
https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/IXI/14050951.html
Good interview on Proactive Investors, worth a watch, plenty to look forward to.
more good news well done IXICO team
Can we see the same this year with the big pharmaceuticals
Great potential hear...I agree expect we will get more exposure very soon
perhaps now we get a wider spread of interest and an introduction to a wider audience to show the potential of ixico